OPKO Health, Inc. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- OPKO Health, Inc. payments for repurchase of common stock for the quarter ending 2026-06-30 was $13.02M, a 28.68% decline year-over-year.
- OPKO Health, Inc. payments for repurchase of common stock for the quarter ending 2026-03-31 was $4.77M.
- OPKO Health, Inc. payments for repurchase of common stock for the quarter ending 2025-12-31 was $13.51M, a 17.96% decline year-over-year.
- OPKO Health, Inc. payments for repurchase of common stock for the quarter ending 2025-09-30 was $15.28M, a 35.70% decline year-over-year.
- OPKO Health, Inc. payments for repurchase of common stock for fiscal 2025 was $47.04M, a 47.86% decline from fiscal 2024.
- OPKO Health, Inc. payments for repurchase of common stock for fiscal 2024 was $90.22M.
- OPKO Health, Inc. payments for repurchase of common stock for fiscal 2023 was $0.00.
- OPKO Health, Inc. payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $13.02M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $46.57M derived: sum of 4 quarters · filed 2026-08-28 |
| 2026-03-31 | $4.77M 10-Q/A · filed 2026-08-28 | $51.81M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-12-31 | $13.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.04M 10-K · filed 2026-02-26 |
| 2025-09-30 | $15.28M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-10-29 | $50.00M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-06-30 | $18.25M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $58.48M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-03-31 | $0.00 10-Q/A · filed 2026-08-28 | $40.22M derived: sum of 4 quarters · filed 2026-08-28 |
| 2024-12-31 | $16.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $90.22M 10-K · filed 2026-02-26 |
| 2024-09-30 | $23.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $73.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $50.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $50.00M 10-Q · filed 2025-05-01 | $50.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | |
| 2013-12-31 | $0.00 10-K · filed 2014-03-03 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-03 | |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $7.83M 10-K · filed 2014-03-03 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |